Exenatide
Side effects
Options:
Show MedDRA Preferred Terms
Side effect
|
Data for drug
|
Placebo
|
Labels
|
|
1
|
2
|
3
|
4
|
5
|
Nausea
|
postmarketing — 1.3% - 44%
|
0% - 18%
|
x
|
x
|
x
|
x
|
x
|
Diarrhoea
|
postmarketing — 3.59% - 20%
|
3% - 8%
|
x
|
x
|
x
|
x
|
x
|
Upper respiratory tract infection
|
1.35% - 17.2%
|
|
|
|
|
|
x
|
Feeling jittery
|
9%
|
4%
|
x
|
x
|
x
|
x
|
|
Headache
|
4.24% - 14%
|
4% - 6%
|
x
|
x
|
x
|
x
|
x
|
Pruritus
|
8%
|
|
x
|
x
|
|
|
x
|
Viral diarrhoea
|
0% - 8.8%
|
|
|
|
|
x
|
x
|
Injection site haematoma
|
0.897% - 11%
|
|
|
|
|
x
|
x
|
Urinary tract infection
|
0.448% - 8.28%
|
|
|
|
|
|
x
|
Dizziness
|
1.35% - 9%
|
6%
|
x
|
x
|
x
|
x
|
x
|
Injection site pruritus
|
0.448% - 18.2%
|
|
|
x
|
|
x
|
x
|
Asthenia
|
4% - 5%
|
1% - 2%
|
x
|
x
|
x
|
x
|
|
Nasopharyngitis
|
2.41% - 17.9%
|
|
|
|
|
|
x
|
Back pain
|
3.03% - 4.22%
|
|
|
|
|
|
x
|
Erythema
|
4%
|
|
x
|
x
|
|
|
x
|
Vomiting
|
postmarketing — 1% - 18.6%
|
0% - 4%
|
x
|
x
|
x
|
x
|
x
|
Induration
|
4%
|
|
|
|
|
|
x
|
Injection site nodule
|
0% - 10.5%
|
|
|
|
|
x
|
x
|
Dyspepsia
|
0.897% - 7.4%
|
0% - 3%
|
x
|
x
|
x
|
x
|
x
|
Constipation
|
postmarketing — 1.2% - 10.1%
|
2%
|
x
|
x
|
x
|
x
|
x
|
Fatigue
|
0% - 6.1%
|
|
|
x
|
|
x
|
x
|
Gastrooesophageal reflux disease
|
0.897% - 7.4%
|
0% - 1%
|
x
|
x
|
x
|
x
|
x
|
Hyperhidrosis
|
3%
|
1%
|
x
|
x
|
x
|
x
|
|
Nodule
|
3%
|
|
|
x
|
|
x
|
x
|
Sinusitis
|
1.2% - 6.9%
|
|
|
|
|
|
x
|
Hypertension
|
1.21% - 3.14%
|
|
|
|
|
|
x
|
Injection site erythema
|
0% - 7.4%
|
|
|
x
|
|
x
|
x
|
Influenza
|
1.2% - 3.14%
|
|
|
|
|
|
x
|
Arthralgia
|
0% - 4.82%
|
|
|
|
|
|
x
|
Cough
|
1.2% - 3.59%
|
|
|
|
|
|
x
|
Musculoskeletal pain
|
0% - 3.14%
|
|
|
|
|
|
x
|
Gastroenteritis
|
0% - 2.03%
|
|
|
|
|
|
x
|
Toothache
|
1.01% - 2.42%
|
|
|
|
|
|
x
|
Abdominal pain upper
|
0.897% - 3.61%
|
|
|
|
|
|
x
|
Oropharyngeal pain
|
0.602% - 3.59%
|
|
|
|
|
|
x
|
Pain in extremity
|
0.69% - 2.41%
|
|
|
|
|
|
x
|
Anxiety
|
0.606% - 2.07%
|
|
|
|
|
|
x
|
Decreased appetite
|
0% - 5%
|
0%
|
x
|
x
|
x
|
x
|
x
|
Depression
|
0% - 2.76%
|
|
|
|
|
|
x
|
Injection site pain
|
0% - 2.07%
|
|
|
|
|
|
x
|
Muscle spasms
|
0.448% - 2.07%
|
|
|
|
|
|
x
|
Abdominal pain
|
postmarketing — 0.897% - 3.61%
|
|
x
|
x
|
x
|
x
|
x
|
Insomnia
|
0.448% - 2.76%
|
|
|
|
|
|
x
|
Hypoglycaemia
|
0% - 43.5%
|
|
x
|
x
|
x
|
x
|
x
|
Anorexia
|
0% - 2.03%
|
|
|
|
|
|
x
|
Injection site induration
|
0% - 3.89%
|
|
|
|
|
|
x
|
Abdominal discomfort
|
0% - 2.2%
|
|
|
|
|
|
x
|
Diabetic neuropathy
|
0% - 2.07%
|
|
|
|
|
|
x
|
Erectile dysfunction
|
0% - 2.76%
|
|
|
|
|
|
x
|
Procedural pain
|
0% - 3.45%
|
|
|
|
|
|
x
|
Abdominal distension
|
postmarketing — 4%
|
1%
|
x
|
x
|
x
|
x
|
x
|
Pancreatitis acute
|
postmarketing, rare
|
|
|
|
x
|
x
|
x
|
Alopecia
|
postmarketing — 0% - 2.07%
|
|
x
|
x
|
x
|
x
|
x
|
Anaphylactic shock
|
very rare, postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
Angioedema
|
postmarketing, rare
|
|
x
|
x
|
x
|
x
|
x
|
Dehydration
|
postmarketing, rare
|
|
x
|
x
|
x
|
x
|
x
|
Dysgeusia
|
postmarketing, uncommon
|
|
x
|
x
|
x
|
x
|
x
|
Eructation
|
postmarketing, uncommon
|
|
x
|
x
|
x
|
x
|
x
|
Flatulence
|
postmarketing — 2%
|
1%
|
x
|
x
|
x
|
x
|
x
|
Haemorrhage
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
Hypersensitivity
|
postmarketing
|
|
|
|
x
|
x
|
|
Renal failure acute
|
postmarketing, rare
|
|
x
|
x
|
x
|
x
|
x
|
Renal failure chronic
|
postmarketing, rare
|
|
|
x
|
x
|
x
|
x
|
Urinary tract disorder
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
Urticaria
|
postmarketing, rare
|
|
x
|
x
|
x
|
x
|
x
|
Weight decreased
|
rare
|
|
x
|
x
|
|
|
x
|
Injection site reaction
|
postmarketing, common
|
|
x
|
x
|
x
|
x
|
x
|
Unspecified disorder of skin and subcutaneous tissue
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
Pancreatitis necrotising
|
postmarketing
|
|
|
|
x
|
x
|
|
Pruritus generalised
|
postmarketing, rare
|
|
|
|
x
|
x
|
x
|
Drug interaction
|
postmarketing
|
|
|
|
x
|
x
|
x
|
Serum creatinine increased
|
postmarketing, rare
|
|
x
|
x
|
x
|
x
|
x
|
Rash papular
|
postmarketing, rare
|
|
x
|
x
|
x
|
x
|
x
|
Renal impairment
|
postmarketing, rare
|
|
x
|
x
|
x
|
x
|
x
|
Somnolence
|
postmarketing, rare
|
|
x
|
x
|
x
|
x
|
x
|
Ischaemia
|
very rare
|
|
|
|
|
|
x
|
Colitis ischaemic
|
very rare
|
|
|
|
|
|
x
|
Ileus
|
very rare
|
|
|
|
|
|
x
|
Alveolitis allergic
|
|
|
|
|
x
|
|
|
Mental disorder
|
|
|
|
|
|
|
x
|
Breast disorder
|
|
|
|
|
|
|
x
|
Chest pain
|
|
|
|
|
x
|
|
|
Coma
|
|
|
|
|
|
x
|
|
Infection
|
|
|
|
|
|
|
x
|
Connective tissue disorder
|
|
|
|
|
|
|
x
|
Gastrointestinal disorder
|
|
|
x
|
x
|
|
|
x
|
Hypokalaemia
|
0% - 2.76%
|
|
|
|
|
|
x
|
Immune system disorder
|
|
|
x
|
x
|
|
|
x
|
Mediastinal disorder
|
|
|
|
|
|
|
x
|
Nervous system disorder
|
|
|
x
|
x
|
|
|
x
|
Renal failure
|
|
|
x
|
|
|
|
|
Convulsion
|
|
|
|
|
|
x
|
|
Tachycardia
|
|
|
|
x
|
|
|
|
Loss of consciousness
|
|
|
|
|
|
x
|
|
Angiopathy
|
|
|
|
|
|
|
x
|
Chills
|
|
|
|
|
x
|
|
|
Injection site mass
|
|
|
|
|
|
x
|
|
Malnutrition
|
|
|
x
|
x
|
|
|
x
|
Diabetic
|
|
|
|
x
|
|
|
x
|
Neuroglycopenia
|
|
|
|
|
|
x
|
|
Injection site dermatitis
|
|
|
|
x
|
|
|
|
Blood glucose decreased
|
|
|
|
x
|
|
|
|
Infestation NOS
|
|
|
|
|
|
|
x
|
International normalised ratio increased
|
|
|
x
|
x
|
|
|
x
|
Indications
Information about indications was extracted from the indications and usage sections of the labels.
Side effects: | 41 |
Source: | EMA |
---|
Side effects: | 49 |
Source: | EMA |
---|
Side effects: | 41 |
Source: | FDA Structured Product Label |
---|
Side effects: | 50 |
Source: | FDA Structured Product Label |
---|
Side effects: | 87 |
Source: | medicines.org.au |
---|
Color scheme:
standard – alternative
|
|
100%
|
|
|
75%
|
|
|
50%
|
|
|
10%
|
|
|
frequent (1% to 100%)
|
|
|
infrequent (0.1% to 1%)
|
|
|
rare (<0.1%)
|
|
|
postmarketing
|
|
|
0%
|
|
|
no frequency information
|
|
|
not found on label
|